Exherin (ADH-1) is a small, cyclic pentapeptide vascular-targeting drug developed by Adherex Technologies[1]. It is indicated for treatment of a variety of invasive carcinomas and has been shown to be synergistic with taxane-based chemotherapy[2]. It has also been evaluated in clinical and pharmacological phase I trials for its potential antineoplastic and antiangiogenic activities[3][4][5]. Invasive ductal carcinoma is one of the common types of breast cancer.

It has been found to be well tolerated with a modest anti tumor effect[3]. Customer reviews suggest that it inhibits N-cadherin mediated cell adhesion[4]. Clinical trials are ongoing to evaluate its efficacy, with one such trial combining ADH-1 with cisplatin and gemcitabine hydrochloride[5].

Common side effects of Exherin include nausea, vomiting, and fatigue[3]. Other potential side effects may include an increased risk of infection and other immune-related adverse events[4][5].

References

1

wikipedia.org
2

nih.gov
3

annalsofoncology.org

4

medchemexpress.com
5

abmole.com